App-Quantinova.ai

Advanced biliary tract cancer: Experience with ABC-02 regimen in a tertiary care center in the United States.

Rishi Agarwal - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Three-dimensional conformal radiotherapy (3D-CRT) for macroscopic vascular invasion (MVI) of advanced hepatocellular carcinoma (HCC).

Akinori Asagi - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Statins improve outcomes of non-surgical curative treatments in hepatocellular carcinoma patients: cohort study from Taiwan cancer registry.

Chia lun Chang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Tuberous sclerosis complex 2 (TSC2) expression in hepatocellular carcinoma to predict responses to mTOR inhibitor.

Jinhyun Cho - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sorafenib

Hepatocellular carcinoma with bone metastases: Incidence, prognostic significance and managementSingle center experience.

Ruchi Bhatia - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Effect of hepatitis C virus (HCV) on the outcome of hepatocellular carcinoma (HCC).

Rangaswamy Govindarajan - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Identification of potentially actionable molecular alterations in advanced hepatocellular carcinoma (HCC).

James J. Harding - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Impact of sorafenib treatment on portal hypertension in hepatocellular carcinoma patients.

Sahin Lacin - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Sorafenib

Next-generation sequencing (NGS) in an advanced hepatocellular carcinoma (HCC) cohort: Analysis of common mutations, clinical covariates, and overall survival (OS).

Robin Kate Kelley - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Temsirolimus

The protective effect of physical activity on risk of hepatocellular carcinoma in USA.

Ahmed S Shalaby - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Variety of hormones produced by rare neuroendocrine tumors (NETs): Examination of epidemiology and prognostic factors for NETs in Italy.

Silvia Fanello - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Simplified/same day (s)-GOLF as first-line treatment of metastatic carcinoma of unknown primary (CUP).

Wasif M. Saif - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Pegfilgrastim

Does OPTINAB strategy ("stop-and-go") work in treatment of advanced pancreatic cancer (APC) with nab-paclitaxel (nab) - gemcitabine (gem)?

Wasif M. Saif - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Gemcitabine

Significant up-regulation of vasodilator-stimulated phosphoprotein in human pancreatic duct adenocarcinoma.

Yifan Tu - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

tPA as marker of thrombosis development after surgical treatment for pancreatic cancer.

Umar Muhmadovich Gaziev - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

General proteolysis as factor of postoperative anastomotic bleeding in cancer of the head of the pancreas.

Larisa Kozlova - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

The fibrinogen/CRP ratio as a novel prognostic parameter for pancreatic cancer patients.

Thomas Winder - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Fibrinogen (IV)

Plasma caveolin-1 level: A prognostic marker for pancreatic cancer.

Nebi Serkan Demirci - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Gemcitabine

Improved overall survival in daily practice of adjuvant chemotherapy in pancreatic cancer patients: Taiwanese single-center study.

Shih-Hung Yang - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Prognostic factors in pancreatic adenocarcinoma: Data from a high resolution cancer registry (HRCR) of Reggio Emilia province.

Romano Sassatelli - American Society of Clinical Oncology (ASCO) , 2016

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

N/A

Filters

41730 Abstracts